Login to Your Account



Array, Novartis Strike MEK Inhibitor Deal Worth up to $467M

By Catherine Hollingsworth


Wednesday, April 21, 2010
Array BioPharma Inc. has snagged another oncology deal involving its MEK inhibitors, this time with Novartis AG in a collaboration that will bring in $45 million up front plus $422 million in milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription